ADMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADMA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has meaningful analyst upside on paper and strong revenue growth, but the current setup is dominated by legal/investigation headlines, credibility concerns around revenue recognition, and weakening profit trends. Since the user is impatient and does not want to wait for a better entry, I would still avoid initiating a new long-term position at this moment and wait for clarity after earnings and the investigations. If forced to choose today, the better call is hold, not buy.
Price is trading at 10.3, below the previous close of 10.6 and below the pivot at 10.825, which keeps the near-term tone weak. RSI_6 at 30.628 is near oversold but not giving a strong reversal confirmation. MACD histogram remains positive at 0.182 but is contracting, which suggests momentum is fading rather than accelerating. Moving averages are converging, pointing to a compressed and indecisive trend. Support is near 10.355 and then 10.065; resistance is 11.295 and 11.585. Overall, the chart is neutral-to-bearish short term, with no strong breakout signal.
["Canaccord initiated coverage with a Buy rating and $21 price target, calling the risk/reward favorable.", "Revenue in Q4 2025 increased 18.39% YoY to 139.163M.", "Gross margin improved to 63.78%, indicating strong operating economics.", "Hedge funds are buying aggressively, with reported buying up 719.51% over the last quarter.", "Options sentiment is bullish, with low put-call ratios indicating call-heavy positioning.", "Earnings are coming on 2026-05-06 after hours, which could provide a catalyst if results are strong."]
["Multiple investigations are ongoing, including Rosen Law Firm, Pomerantz LLP, and Bleichmar Fonti & Auld LLP, all tied to potential securities/fraud claims.", "A short report by Culper Research alleged channel stuffing and said reported growth may be overstated.", "Cantor Fitzgerald downgraded the stock to Neutral amid the controversy and concerns about receivables and days sales outstanding.", "Net income fell 55.87% YoY in the latest quarter despite revenue growth.", "EPS dropped 55.56% YoY, showing weaker bottom-line performance.", "The stock has experienced severe recent price damage, reflecting damaged market confidence.", "Insider activity is neutral, so there is no insider buying signal to offset the negative news flow."]
In Q4 2025, ADMA showed solid top-line growth, with revenue rising 18.39% YoY to 139.163M. Gross margin also improved to 63.78%, which is a strong sign for long-term operating quality. However, profitability weakened sharply: net income fell 55.87% YoY to 49.379M and EPS declined 55.56% YoY to 0.20. So the latest quarter season was strong on revenue and margins, but weak on earnings growth, which reduces confidence in the durability of the story.
Analyst sentiment is mixed but still has upside potential. The latest trend is bullish from Canaccord, which initiated coverage with a Buy and $21 target, and Mizuho still has Outperform with a lowered target of $24 from $30. Against that, Cantor Fitzgerald downgraded the stock to Neutral from Overweight after the short report and investor concern over revenue quality. Wall Street pros see a possible valuation recovery if growth is real and margins hold, but the cons view is that accounting credibility, receivables, and disclosure concerns may be masking weaker underlying demand. Overall, analysts are split, but the recent price-target support is stronger than the downgrades, even though the controversy keeps conviction limited.
